| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CARS1; CYSRS; MGC:11246 |
| Entrez GeneID | 833 |
| WB Predicted band size | Calculated MW: 85 kDa; Observed MW: 85 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthetic peptide of human CARS |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于抗合成酶抗体(Anti-synthetase Antibodies，可能与“CARS抗体”相关)的模拟参考文献示例(注：文献为虚构示例，实际研究需参考真实数据库)：
---
1. **标题**：*Anti-Jo-1 Antibodies in Idiopathic Inflammatory Myopathies: Clinical Correlations and Diagnostic Utility*
**作者**：Smith A, et al.
**摘要**：本研究分析了抗Jo-1抗体(一种抗合成酶抗体)在多发性肌炎和皮肌炎患者中的分布，发现其与间质性肺病(ILD)和“机械手”综合征显著相关。文章提出抗Jo-1抗体可作为疾病分型和预后的生物标志物。
2. **标题**：*Novel Anti-PL-12 Antibody Detection and Its Association with Rapidly Progressive ILD*
**作者**：Chen L, et al.
**摘要**：通过回顾性队列研究，发现抗PL-12抗体阳性的患者更易出现快速进展的间质性肺病，且对传统免疫治疗反应较差。研究强调了早期筛查该抗体对改善预后的意义。
3. **标题**：*Mechanistic Insights into Anti-Synthetase Syndrome: Role of Autoantibodies in Muscle Inflammation*
**作者**：Garcia R, et al.
**摘要**：通过小鼠模型揭示了抗合成酶抗体通过激活干扰素信号通路和促进肌细胞凋亡的机制，为靶向治疗(如JAK抑制剂)提供了理论依据。
4. **标题**：*Comparative Analysis of Anti-MDA5 and Anti-Synthetase Antibodies in Dermatomyositis*
**作者**：Watanabe K, et al.
**摘要**：对比抗MDA5抗体与抗合成酶抗体(如抗Jo-1、抗EJ)的临床表现差异，发现前者与皮肤溃疡和急性肺损伤相关，而后者更多合并关节炎和慢性ILD。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词：**anti-synthetase antibodies**, **myositis**, **interstitial lung disease**。
Chimeric antigen receptor (CAR) antibodies, often associated with CAR-T cell therapy, represent a groundbreaking approach in immunotherapy. CARs are synthetic receptors engineered to redirect immune cells, typically T cells, to recognize and eliminate specific cancer cells. The concept emerged in the late 1980s, combining antibody-derived antigen-binding domains with T-cell signaling components. Early CAR designs fused single-chain variable fragments (scFv) from monoclonal antibodies to intracellular signaling domains like CD3ζ, enabling antigen-specific T-cell activation without MHC restriction.
Over decades, CAR structures evolved through "generations" incorporating co-stimulatory domains (e.g., CD28. 4-1BB) to enhance persistence and efficacy. This innovation addressed limitations in early CAR-T cells, which showed poor expansion and transient activity. The first FDA approval in 2017 (tisagenlecleucel for B-cell malignancies) marked a therapeutic milestone, demonstrating remarkable remission rates in refractory cancers.
CAR antibodies extend beyond T cells, with ongoing research exploring CAR-NK cells and macrophages. Challenges remain in managing cytokine release syndrome, improving solid tumor targeting, and reducing manufacturing complexity. Current advancements focus on universal off-the-shelf CAR products, logic-gated systems for precision, and combination therapies. These engineered antibodies exemplify the convergence of genetic engineering and immunology, revolutionizing personalized cancer treatment while expanding into autoimmune and infectious disease applications.
×
